| Literature DB >> 26420062 |
Annemarie M J Braamse1,2, B van Meijel3,4,5, O J Visser6, A D Boenink3, P Cuijpers7, C E Eeltink6, A W Hoogendoorn3, M van Marwijk Kooy8, P van Oppen3, P C Huijgens6, A T F Beekman3, J Dekker3,9.
Abstract
Psychological distress contributes to impaired quality of life in hematological cancer patients. Stepped care treatment, in which patients start with the least intensive treatment most likely to work and only receive more intensive interventions if needed, could improve distress. We aimed to evaluate the outcome of stepped care treatment on psychological distress and physical functioning in patients treated with autologous stem cell transplantation for hematological malignancies. In the present study, we performed a randomized clinical trial with two treatment arms: stepped care and care as usual. Baseline assessment and randomization occurred during pre-transplant hospitalization. Stepped care was initiated after 6 weeks, consisting of (1) watchful waiting, (2) Internet-based self-help intervention, and (3) face-to-face counseling/ psychopharmacological treatment/ referral. Follow-up measurements were conducted at 13, 30, and 42 weeks after transplantation. Stepped care (n = 47) and care as usual (n = 48) were comparable on baseline characteristics. The uptake of the intervention was low: 24 patients started with step 1, 23 with step 2, and none with step 3. Percentages of distressed patients ranged from 4.1 to 9.7 %. Ten percent of patients received external psychological or psychiatric care. No statistically significant differences were found between stepped care and care as usual on psychological distress or physical functioning in intention to treat analyses, nor in per protocol analyses. The stepped care program was not effective in decreasing psychological distress. The low intervention uptake, probably related to the low levels of psychological distress, offers an explanation for this outcome. Future research should take into account patients' specific care needs. Netherlands Trial Registry identifier: NTR1770.Entities:
Keywords: Anxiety; Depression; Hematological neoplasms; Hematopoietic stem cell transplantation; Quality of life
Mesh:
Year: 2015 PMID: 26420062 PMCID: PMC4700101 DOI: 10.1007/s00277-015-2509-6
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673
Fig. 1Design of the randomized clinical trial/CONSORT flow diagram
Sample characteristics
| Stepped care ( | Care as usual ( |
| |
|---|---|---|---|
| Gender, female, | 16 (34.0) | 14 (29.2) | 0.61 |
| Age in years, mean (s.d.) | 53.3 (8.7) | 55.5 (8.7) | 0.23 |
| BMI, mean (s.d.) | 25.8 (4.0) | 26.4 (3.2) | 0.41 |
| Living with partner, yes, | 33 (70.2) | 40 (85.1) | 0.08 |
| Education, | 0.06 | ||
| <4-year college degree | 16 (34.0) | 25 (53.2) | |
| ≥4-year college degree | 31 (66.0) | 22 (46.8) | |
| Diagnosis, | 0.77 | ||
| Non-Hodgkin lymphoma | 19 (40.4) | 17 (35.4) | |
| Hodgkin lymphoma | 5 (10.6) | 4 (8.3) | |
| Multiple myeloma | 23 (48.9) | 27 (56.3) | |
| Type of conditioning, | 0.36 | ||
| High-dose melphalan (HDM) | 23 (48.9) | 28 (58.3) | |
| BEAM/Z-BEAM | 24 (51.1) | 19 (39.6) | |
| Busulfan/cyclofosfamide | – | 1 (2.1) | |
| Somatic comorbidities, | 0.39 | ||
| None | 6 (12.8) | 2 (4.3) | |
| 1 | 19 (40.4) | 18 (38.3) | |
| 2 | 8 (17.0) | 12 (25.5) | |
| 3 or more | 14 (29.8) | 15 (31.9) | |
| Remission status at time of transplantb | 0.85 | ||
| Complete remission | 19 (44.2) | 19 (42.2) | |
| Not in complete remission | 24 (55.8) | 26 (57.8) |
aCare as usual: 1 patient missing data
bStepped care: 4 patients missing data; care as usual: 3 patients missing data
Percentages of patients with psychological distress
| T0 | T13 | T30 | T42 | ||
|---|---|---|---|---|---|
| Total | Total | Total | Total | ||
| Psychological distress | Total group | 7.5 | 4.1 | 9.7 | 8.5 |
| Stepped care | 4.3 | 8.3 | 13.3 | 14.3 | |
| Care as usual | 10.9 | 0 | 6.3 | 3.2 | |
| Depression | Total group | 7.5 | 9.6 | 11.3 | 10.2 |
| Stepped care | 2.1 | 11.1 | 10.0 | 10.7 | |
| Care as usual | 13.0 | 8.1 | 12.5 | 9.7 | |
| Anxiety | Total group | 6.5 | 8.2 | 12.9 | 11.9 |
| Stepped care | 6.4 | 8.3 | 16.7 | 17.9 | |
| Care as usual | 6.5 | 8.1 | 9.4 | 6.5 | |
| Depression | Total group | 16.0 | 5.4 | 12.9 | 8.5 |
| Stepped care | 12.8 | 8.3 | 13.3 | 10.7 | |
| Care as usual | 19.1 | 2.6 | 12.5 | 6.5 | |
| Anxiety | Total group | 27.7 | 19.2 | 19.4 | 20.3 |
| Stepped care | 23.4 | 22.2 | 16.7 | 14.3 | |
| Care as usual | 31.9 | 16.2 | 21.9 | 25.8 |
SC stepped care, CAU care as usual, HADS Hospital Anxiety and Depression Scale, PHQ Patient Health Questionnaire, STAI Spielberger State-Trait Anxiety Inventory
Observed mean scores of primary and secondary outcomes
| Stepped care | Care as usual | ||
|---|---|---|---|
| Mean (s.d.) | Mean (s.d.) | ||
|
| |||
| Psychological distress | T0 | 6.72 (4.47) | 7.26 (4.90) |
| T13 | 6.69 (4.96) | 5.75 (3.45) | |
| T30 | 6.53 (6.06) | 6.38 (5.93) | |
| T42 | 6.54 (6.44) | 6.29 (4.55) | |
| Depression | T0 | 2.98 (2.24) | 3.52 (3.38) |
| T13 | 3.17 (2.55) | 2.73 (2.51) | |
| T30 | 2.63 (2.91) | 3.13 (4.03) | |
| T42 | 2.64 (2.88) | 2.87 (3.03) | |
| Anxiety | T0 | 3.74 (2.88) | 3.74 (2.64) |
| T13 | 3.53 (2.89) | 3.03 (2.21) | |
| T30 | 3.90 (3.58) | 3.25 (2.75) | |
| T42 | 3.89 (3.93) | 3.42 (2.43) | |
| Physical functioning | T0 | 74.47 (20.06) | 70.64 (19.59) |
| T13 | 74.25 (21.91) | 74.05 (19.55) | |
| T30 | 82.22 (17.00) | 79.79 (23.74) | |
| T42 | 83.10 (15.76) | 82.80 (18.28) | |
|
| |||
| Emotional functioning | T0 | 80.50 (17.83) | 79.89 (16.16) |
| T13 | 82.41 (16.64) | 87.84 (13.55) | |
| T30 | 84.17 (17.28) | 84.38 (14.93) | |
| T42 | 83.93 (17.85) | 81.18 (14.59) | |
| Role functioning | T0 | 59.22 (35.24) | 57.09 (34.18) |
| T13 | 68.06 (28.56) | 66.67 (24.46) | |
| T30 | 75.00 (27.60) | 75.52 (29.63) | |
| T42 | 74.40 (27.02) | 74.19 (27.50) | |
| Anxiety | T0 | 35.06 (8.74) | 35.15 (8.18) |
| T13 | 32.97 (8.76) | 31.57 (7.90) | |
| T30 | 32.60 (10.22) | 33.44 (10.33) | |
| T42 | 32.89 (11.93) | 33.10 (9.69) | |
| Depression | T0 | 5.66 (4.07) | 4.87 (4.96) |
| T13 | 4.61 (3.72) | 3.82 (2.65) | |
| T30 | 3.93 (4.16) | 4.84 (5.73) | |
| T42 | 4.14 (3.66) | 3.68 (3.45) | |
| Problem solving | T0 | 133.36 (19.86) | 137.34 (18.36) |
| T13 | 138.86 (12.43) | 135.56 (20.92) | |
| T30 | 137.48 (14.11) | 139.25 (17.29) | |
| T42 | 140.41 (17.46) | 136.63 (18.58) | |
| Self-efficacy | T0 | 31.79 (3.92) | 32.20 (5.28) |
| T13 | 33.28 (4.42) | 32.38 (4.95) | |
| T30 | 33.17 (4.15) | 31.94 (5.10) | |
| T42 | 33.07 (4.95) | 31.57 (6.04) | |
HADS Hospital Anxiety and Depression Scale, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, SPSI-R Social Problem Solving Inventory-Revised, DGSS Dutch General Self-efficacy Scale, PHQ Patient Health Questionnaire, STAI Spielberger State-Trait Anxiety Inventory
Test statistics and effect sizes of the differences in primary and secondary outcomes between the experimental group and the control group, from linear mixed model analyses
|
|
| Effect size | ||
|---|---|---|---|---|
|
| ||||
| Psychological distress | Condition*T13 | 1.40 | 0.16 | 0.28 |
| Condition*T30 | 0.47 | 0.64 | 0.10 | |
| Condition*T42 | 0.50 | 0.62 | 0.11 | |
| Depression | Condition*T13 | 1.31 | 0.19 | 0.30 |
| Condition*T30 | −0.10 | 0.92 | −0.02 | |
| Condition*T42 | 0.05 | 0.96 | 0.01 | |
| Anxiety | Condition*T13 | 0.90 | 0.37 | 0.18 |
| Condition*T30 | 0.97 | 0.33 | 0.21 | |
| Condition*T42 | 0.87 | 0.39 | 0.19 | |
| Physical functioning | Condition*T13 | −1.00 | 0.32 | −0.19 |
| Condition*T30 | −0.53 | 0.60 | −0.11 | |
| Condition*T42 | −0.12 | 0.91 | −0.02 | |
|
| ||||
| Emotional functioning | Condition*T13 | −2.32 | 0.02* | −0.43 |
| Condition*T30 | −0.94 | 0.35 | −0.19 | |
| Condition*T42 | 0.12 | 0.91 | 0.02 | |
| Role functioning | Condition*T13 | −0.09 | 0.93 | −0.02 |
| Condition*T30 | −0.52 | 0.60 | −0.11 | |
| Condition*T42 | 0.15 | 0.89 | 0.03 | |
| Anxiety | Condition*T13 | 0.99 | 0.33 | 0.21 |
| Condition*T30 | −0.29 | 0.77 | −0.07 | |
| Condition*T42 | 0.16 | 0.87 | 0.04 | |
| Depression | Condition*T13 | 0.09 | 0.93 | 0.02 |
| Condition*T30 | −1.32 | 0.19 | −0.31 | |
| Condition*T42 | −0.54 | 0.59 | −0.13 | |
| Problem-solving | Condition*T13 | 1.59 | 0.11 | 0.29 |
| Condition*T30 | 1.02 | 0.31 | 0.20 | |
| Condition*T42 | 1.61 | 0.11 | 0.32 | |
| Self-efficacy | Condition*T13 | 0.99 | 0.33 | 0.19 |
| Condition*T30 | 1.27 | 0.21 | 0.26 | |
| Condition*T42 | 1.40 | 0.16 | 0.29 | |
HADS Hospital Anxiety and Depression Scale, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, SPSI-R Social Problem Solving Inventory-Revised, DGSS Dutch General Self-efficacy Scale, PHQ Patient Health Questionnaire, STAI Spielberger State-Trait Anxiety Inventory
*P < 0.05